Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 28;19(2):1863-1872.
doi: 10.1007/s40200-020-00619-9. eCollection 2020 Dec.

A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity

Mandana Hasanzad  1   2 , Negar Sarhangi  2 , Shekoufeh Nikfar  2   3 , Seyed Naser Ostad  2   4 , Hamid Reza Aghaei Meybodi  2   5
Affiliations
Review

A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity

Mandana Hasanzad et al. J Diabetes Metab Disord. .

Abstract

Liraglutide is a long-acting human glucagon-like peptide-1 (GLP-1) analogue and an effective treatment for patients with metabolic diseases including type 2 diabetes mellitus (T2DM) and obesity. This review focuses on the mechanism of action of liraglutide as a well-known glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients with T2DM and obesity. The lower and the higher doses of GLP-1 RAs are used for glycaemic control in T2DM and in obesity respectively. GLP-1 RAs such as liraglutide enhance insulin secretion and inhibit glucagon release via the stimulation of glucagon-like peptide-1 receptors (GLP-1Rs). Liraglutide decreases hemoglobin A1c (HbA1c) in type 2 diabetes (T2D) patients when prescribes as monotherapy or in combination with one or more antidiabetic drugs. Usually, it is well tolerated with minor hypoglycemia in combination therapy. Liraglutide reduces cardiovascular events and related risk factors including improvement of lipid profile and control of blood pressure. Accordingly, it can be cost-effective and may be a budget neutral medication option by considering its protective effect on the cardiovascular system in long-term use in the health care plan. In the near future, by pharmacogenomics approach, prediction of the highest patient's response with the lowest adverse drug reactions and also rationality of drug development will be possible. Liraglutide can be used as a desirable medicine for glycemic control and obesity. It shows extensive evidence based benefits in diabetes complications. In this narrative review, we have summarized and evaluated studies related to the role of liraglutide in clinical practice.

Keywords: Cardiovascular events; GLP-1 RAs, Liraglutide; Obesity; Pharmacogenomics; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interests.

Figures

Fig. 1
Fig. 1
Liraglutide and pathophysiological conditions
See this image and copyright information in PMC

References

    1. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4(2):113–119. - PMC - PubMed
    1. International Diabetes Federation (IDF). IDF Diabetes Atlas - 8th Edition. 2017. https://diabetesatlas.org/resources/2017-atlas.html. - PubMed
    1. Care D. Standards of Medical Care in Diabetesd 2019. Diabetes Care. 2019;42:S81. - PubMed
    1. Peykari N, Hashemi H, Dinarvand R, Haji-Aghajani M, Malekzadeh R, Sadrolsadat A, Sayyari AA, Asadi-lari M, Delavari A, Farzadfar F, Haghdoost A, Heshmat R, Jamshidi H, Kalantari N, Koosha A, Takian A, Larijani B. National action plan for non-communicable diseases prevention and control in Iran; a response to emerging epidemic. J Diabetes Metab Disord. 2017;16(1):3. - PMC - PubMed
    1. DeFronzo RA. From the triumvirate to the „ominous octet”: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4): 773–795. - PMC - PubMed

LinkOut - more resources